> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Since Our Last Issue ...
- URL: https://www.fdaweb.com/since-our-last-issue-97/
- Published: 2017-05-21T12:00:00.000Z
- Updated: 2026-09-14T22:24:50.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5138747

**AstraZeneca** has sold the European commercial rights to its beta-blocker heart drug Seloken and the associated fixed-dose combination Logimax to Italy-based **Recordati** for $300 million. Seloken (metroprolol) is used to control conditions such as hypertension, angina pectoris, disturbances of cardiac rhythm, maintenance treatment after myocardial infarction and functional heart disorders with palpitations. Logimax is the fixed-dose combination of metoprolol succinate with felodipine. It is indicated for the control of hypertension.  
  
**DePuy Synthes Products** has acquired 3D printing technology from medical device company **Tissue Regeneration Systems Inc.** (TRS). The 3D printing methods developed by TRS will help enable DePuy Synthes to create patient-specific, bioresorbable implants with a unique mineral coating intended to support bone healing in patients with orthopedic and craniomaxillofacial deformities and injuries. Financial terms of the transaction have not been disclosed.  
  
**Hitachi Chemical Co. America** has acquired **PCT Cell Therapy Services**, a leading contract development and manufacturing organization for the cell therapy industry. The completed acquisition allows Hitachi Chemical to fully leverage PCT’s extensive experience in cell therapy development and manufacturing technology, wide-ranging manufacturing locations, sales network, and other resources to expand and strengthen its services in the U.S. and add services in Japan, Europe and other regions.